JP2002533335A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002533335A5 JP2002533335A5 JP2000589530A JP2000589530A JP2002533335A5 JP 2002533335 A5 JP2002533335 A5 JP 2002533335A5 JP 2000589530 A JP2000589530 A JP 2000589530A JP 2000589530 A JP2000589530 A JP 2000589530A JP 2002533335 A5 JP2002533335 A5 JP 2002533335A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- tumor cells
- aryl
- ring
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 description 27
- 210000004881 tumor cell Anatomy 0.000 description 26
- 125000000217 alkyl group Chemical group 0.000 description 22
- 125000003118 aryl group Chemical group 0.000 description 17
- 125000001424 substituent group Chemical group 0.000 description 14
- 125000003710 aryl alkyl group Chemical group 0.000 description 11
- 229910052799 carbon Inorganic materials 0.000 description 11
- 125000000753 cycloalkyl group Chemical group 0.000 description 11
- 150000001721 carbon Chemical group 0.000 description 7
- 125000005843 halogen group Chemical group 0.000 description 7
- 125000001072 heteroaryl group Chemical group 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 5
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 5
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- -1 benzotriazol-1-yloxy, tetrazol-5-ylthio Chemical group 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 125000000547 substituted alkyl group Chemical group 0.000 description 4
- 206010005003 Bladder cancer Diseases 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 3
- 102000004357 Transferases Human genes 0.000 description 3
- 108090000992 Transferases Proteins 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 125000004030 farnesyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000000066 myeloid cell Anatomy 0.000 description 3
- 208000025113 myeloid leukemia Diseases 0.000 description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 description 3
- 201000002528 pancreatic cancer Diseases 0.000 description 3
- 208000023958 prostate neoplasm Diseases 0.000 description 3
- 210000001685 thyroid gland Anatomy 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 201000001531 bladder carcinoma Diseases 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 2
- MCTWTZJPVLRJOU-UHFFFAOYSA-N C[n]1cncc1 Chemical compound C[n]1cncc1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101150040459 RAS gene Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000004422 alkyl sulphonamide group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 125000005140 aralkylsulfonyl group Chemical group 0.000 description 1
- 125000003435 aroyl group Chemical group 0.000 description 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 125000004421 aryl sulphonamide group Chemical group 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N c1ccncc1 Chemical compound c1ccncc1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 108700042226 ras Genes Proteins 0.000 description 1
- 102000016914 ras Proteins Human genes 0.000 description 1
- 108010014186 ras Proteins Proteins 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21656098A | 1998-12-18 | 1998-12-18 | |
| US09/216,560 | 1998-12-18 | ||
| PCT/US1999/027938 WO2000037458A1 (en) | 1998-12-18 | 1999-12-16 | Farnesyl protein transferase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002533335A JP2002533335A (ja) | 2002-10-08 |
| JP2002533335A5 true JP2002533335A5 (enExample) | 2007-02-08 |
Family
ID=22807539
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000589530A Pending JP2002533335A (ja) | 1998-12-18 | 1999-12-16 | ファルネシルタンパク質トランスフェラーゼインヒビター |
Country Status (23)
| Country | Link |
|---|---|
| EP (1) | EP1140904B1 (enExample) |
| JP (1) | JP2002533335A (enExample) |
| KR (1) | KR20010081115A (enExample) |
| CN (1) | CN1285588C (enExample) |
| AR (1) | AR021716A1 (enExample) |
| AT (1) | ATE293622T1 (enExample) |
| AU (1) | AU2347900A (enExample) |
| BR (1) | BR9916328A (enExample) |
| CA (1) | CA2354774C (enExample) |
| CO (1) | CO5160344A1 (enExample) |
| CZ (1) | CZ20011900A3 (enExample) |
| DE (1) | DE69924876T2 (enExample) |
| ES (1) | ES2237963T3 (enExample) |
| HU (1) | HUP0203054A3 (enExample) |
| ID (1) | ID29065A (enExample) |
| IL (1) | IL143409A0 (enExample) |
| NO (1) | NO20012960L (enExample) |
| PE (1) | PE20001516A1 (enExample) |
| PL (1) | PL348294A1 (enExample) |
| SK (1) | SK7582001A3 (enExample) |
| TR (1) | TR200101754T2 (enExample) |
| WO (1) | WO2000037458A1 (enExample) |
| ZA (1) | ZA200104236B (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1263726B1 (en) * | 1999-11-10 | 2007-09-26 | Sanofi-Aventis Deutschland GmbH | N-acylpyrrolidin-2-ylalkylbenzamidine derivatives as inhibitors of factor xa |
| US7361663B2 (en) | 1999-11-10 | 2008-04-22 | Aventis Pharmaceuticals Inc. | N-acylpyrrolidin-2-ylalkylbenzamidine derivatives as inhibitors of factor Xa |
| US6589978B2 (en) | 2000-06-30 | 2003-07-08 | Hoffman-La Roche Inc. | 1-sulfonyl pyrrolidine derivatives |
| US7342016B2 (en) | 2000-08-30 | 2008-03-11 | Schering Corporation | Farnesyl protein transferase inhibitors as antitumor agents |
| AR033680A1 (es) * | 2000-08-30 | 2004-01-07 | Schering Corp | Compuestos triciclicos utiles como inhibidores de la farnesil proteino transferasa y su uso para la manufactura de medicamentos como agentes antitumorales |
| US6693099B2 (en) | 2000-10-17 | 2004-02-17 | The Procter & Gamble Company | Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance |
| US6809093B2 (en) | 2000-10-17 | 2004-10-26 | H. Lee Moffitt Cancer & Research Institute, Inc. | 2-substituted heterocyclic compounds |
| US6376514B1 (en) | 2000-10-17 | 2002-04-23 | The Procter & Gamble Co. | Substituted six-membered heterocyclic compounds useful for treating multidrug resistance and compositions and methods thereof |
| US6645966B2 (en) | 2001-01-22 | 2003-11-11 | Schering Corporation | Treatment of malaria with farnesyl protein transferase inhibitors |
| ATE412638T1 (de) | 2001-02-16 | 2008-11-15 | Aventis Pharma Inc | Heterocyclische substituierte carbonyl derivate und ihre verwendung als dopamin d3 rezeptor liganden |
| WO2002080895A2 (en) * | 2001-04-06 | 2002-10-17 | Schering Corporation | Treatment of malaria with farsenyl protein transferase inhibitors |
| FR2825705B1 (fr) * | 2001-06-08 | 2005-05-20 | Aventis Pharma Sa | Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens |
| GB0115862D0 (en) | 2001-06-28 | 2001-08-22 | Smithkline Beecham Plc | Compounds |
| US6740757B2 (en) * | 2001-08-29 | 2004-05-25 | Pfizer Inc | Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer |
| FR2835186B1 (fr) | 2002-01-28 | 2006-10-20 | Aventis Pharma Sa | Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases |
| FR2844273B1 (fr) | 2002-09-05 | 2008-04-04 | Aventis Pharma Sa | Nouveaux composes heterocycliques, procede et intermediaires de preparation et utilisation comme medicament, notamment comme inhibiteurs de beta-lactamases et anti-bacteriens. |
| CN1744930A (zh) * | 2002-12-17 | 2006-03-08 | 先灵公司 | 治疗雄激素依赖性疾病的3型17β－羟基类固醇脱氢酶抑制剂 |
| CA2590979A1 (en) | 2004-12-13 | 2006-06-22 | Schering Corporation | Novel farnesyl protein transferase inhibitors and their use to treat cancer |
| CA2591123A1 (en) | 2004-12-14 | 2006-06-22 | Schering Corporation | Farnesyl protein transferase inhibitors and methods for treating proliferative diseases |
| CN101400656A (zh) * | 2006-01-19 | 2009-04-01 | 先灵公司 | 作为法呢基蛋白转移酶抑制剂的哌嗪衍生物 |
| US8674093B2 (en) * | 2008-05-22 | 2014-03-18 | Merck Canada Inc. | Process for the preparation of an orexin receptor antagonist |
| HU231150B1 (hu) | 2017-03-13 | 2021-03-29 | Richter Gedeon Nyrt | Eljárás racém 3-alkilpiperidin-3-karbonsav-etil-észterek optikai izomerjeinek elválasztására |
| JP2022534704A (ja) | 2019-06-04 | 2022-08-03 | ヘイガー バイオサイエンシズ，エルエルシー | オレキシンアンタゴニストとしてのイミダゾロ誘導体、組成物、及び方法 |
| AU2021319420A1 (en) | 2020-08-05 | 2023-03-16 | Richter Gedeon Nyrt. | Pharmacologically active heterocyclic-substituted pyrazolo[1,5-a]pyrimidine derivatives |
| CN114349711B (zh) * | 2022-02-28 | 2023-08-15 | 四川依维欣医药科技有限公司 | 一种（R）-1-Boc-3-羟甲基哌嗪的合成方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL111235A (en) * | 1993-10-15 | 2001-03-19 | Schering Plough Corp | Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them |
| GB9420172D0 (en) * | 1994-10-06 | 1994-11-23 | Boots Co Plc | Therapeutic agents |
| IL117798A (en) * | 1995-04-07 | 2001-11-25 | Schering Plough Corp | Tricyclic compounds useful for inhibiting the function of protein - G and for the treatment of malignant diseases, and pharmaceutical preparations containing them |
| ES2224408T3 (es) * | 1997-06-17 | 2005-03-01 | Schering Corporation | Compuestos de benzopiridocicloheptano utiles para la inhibicion de la farnesil-proteina-transferasa. |
-
1999
- 1999-12-16 BR BR9916328-4A patent/BR9916328A/pt not_active IP Right Cessation
- 1999-12-16 AU AU23479/00A patent/AU2347900A/en not_active Abandoned
- 1999-12-16 IL IL14340999A patent/IL143409A0/xx unknown
- 1999-12-16 TR TR2001/01754T patent/TR200101754T2/xx unknown
- 1999-12-16 DE DE69924876T patent/DE69924876T2/de not_active Expired - Fee Related
- 1999-12-16 PL PL99348294A patent/PL348294A1/xx not_active Application Discontinuation
- 1999-12-16 AR ARP990106459A patent/AR021716A1/es unknown
- 1999-12-16 HU HU0203054A patent/HUP0203054A3/hu unknown
- 1999-12-16 KR KR1020017007535A patent/KR20010081115A/ko not_active Withdrawn
- 1999-12-16 WO PCT/US1999/027938 patent/WO2000037458A1/en not_active Ceased
- 1999-12-16 ES ES99967139T patent/ES2237963T3/es not_active Expired - Lifetime
- 1999-12-16 AT AT99967139T patent/ATE293622T1/de not_active IP Right Cessation
- 1999-12-16 CA CA002354774A patent/CA2354774C/en not_active Expired - Fee Related
- 1999-12-16 CZ CZ20011900A patent/CZ20011900A3/cs unknown
- 1999-12-16 ID IDW00200101310A patent/ID29065A/id unknown
- 1999-12-16 CO CO99078838A patent/CO5160344A1/es unknown
- 1999-12-16 JP JP2000589530A patent/JP2002533335A/ja active Pending
- 1999-12-16 SK SK758-2001A patent/SK7582001A3/sk unknown
- 1999-12-16 EP EP99967139A patent/EP1140904B1/en not_active Expired - Lifetime
- 1999-12-16 CN CNB998162078A patent/CN1285588C/zh not_active Expired - Fee Related
- 1999-12-17 PE PE1999001293A patent/PE20001516A1/es not_active Application Discontinuation
-
2001
- 2001-05-23 ZA ZA200104236A patent/ZA200104236B/en unknown
- 2001-06-15 NO NO20012960A patent/NO20012960L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002533335A5 (enExample) | ||
| EP3277276B1 (en) | Methods of administering glutaminase inhibitors | |
| EP2990057B1 (en) | Pai-1 inhibitor for use in enhancing the antitumor effect of an antitumor agent in a patient | |
| KR20150123328A (ko) | 암 치료용 화합물 | |
| KR920700200A (ko) | 19-노르-비타민 d 화합물 | |
| RU2003132534A (ru) | Ингибиторы ингибирующего фактора миграции макрофага и способы их идентифицирования | |
| CA2960876C (en) | Combination therapy of inhibitors of c-c chemokine receptor type 9 (ccr9) and anti-alha4beta7 integrin blocking antibodies | |
| CN111170991A (zh) | 抗增殖化合物及其合成方法 | |
| JP7322036B2 (ja) | Ｃｃｒ６またはｃｘｃｒ２のアンタゴニストを用いて汎発性膿疱性乾癬を治療する方法 | |
| EP2694073B1 (en) | Combinations of akt and mek inhibitors for treating cancer | |
| RU2014154009A (ru) | Комбинация ингибитора 17-альфа-гидроксилазы (с17,20-лиазы) и специфического ингибитора pi-3k для лечения онкологического заболевания | |
| CA2617991A1 (en) | N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof | |
| EP3978017A1 (en) | Combination cancer therapy using sulfonamide compound and immunomodulatory | |
| US20180250261A1 (en) | Method for treating cancer with a stat3 pathway inhibitor and kinase inhibitor | |
| CN115397820A (zh) | 用于治疗骨髓增生性肿瘤的赖氨酸特异性组蛋白脱甲基化酶抑制剂 | |
| US20210380547A1 (en) | Urea derivatives for treating and/or preventing cancer | |
| JPWO2022029138A5 (enExample) | ||
| RU2004111787A (ru) | Ретиноидные агонисты (1), производные алкилмочевины | |
| RU98119949A (ru) | АНТАГОНИСТЫ α-АДРЕНЭРГИЧЕСКОГО РЕЦЕПТОРА | |
| RU2001124601A (ru) | Фенилаланиловые производные | |
| JP2023526442A (ja) | Ｒｏｎ変異体が関与する小細胞肺がんの予防又は治療用医薬組成物及びその使用方法 | |
| JP2008545803A5 (enExample) | ||
| JP2002533336A5 (enExample) | ||
| KR20000075769A (ko) | 디아미노트리플루오로메틸피리딘 유도체를 포함하는 항암 조성물 | |
| TW201406759A (zh) | Ｖｅｇｆｒ－３抑制劑於治療肝細胞癌之用途 |